The Food and Drug Administration on Thursday granted full approval for the first time to an experimental Alzheimer's drug, triggering a process that could expand coverage of the $26,500 treatment to millions of patients.
Why it matters: Eisai and Biogen's Leqembi was found to have modest success slowing the disease's progression in clinical trials, by delaying cognitive decline by 27% over 18 months.